Debora Fumagalli
Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
Pizzamiglio S, Cappelletti V, Cinieri S, Piccart M, Daidone M, Pruneri G, Colombo M, Tagliabue E, Verderio P, Huober J, Nuciforo P, Izquierdo M, Ciniselli C, Triulzi T, Gargiuli C, De Cecco L, de Azambuja E, Fumagalli D, Sotiriou C, Harbeck N, Di Cosimo S. Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. Clin Cancer Res 2021; 27:6307-6313.
Sep 21, 2021Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
Sep 21, 2021Clin Cancer Res 2021; 27:6307-6313
Pizzamiglio Sara, Cappelletti Vera, Cinieri Saverio, Piccart Martine, Daidone Maria Grazia, Pruneri Giancarlo, Colombo Mario Paolo, Tagliabue Elda, Verderio Paolo, Huober Jens, Nuciforo Paolo, Izquierdo Miguel, Ciniselli Chiara Maura, Triulzi Tiziana, Gargiuli Chiara, De Cecco Loris, de Azambuja Evandro, Fumagalli Debora, Sotiriou Christos, Harbeck Nadia, Di Cosimo Serena
Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III clinical trial
Venet D, Gomez H, Semiglazov V, de Azambuja E, Huober J, Nuciforo P, Di Cosimo S, Piccart-Gebhart M, Loi S, Rothé F, Saura C, Wang Y, Rediti M, Maetens M, Fumagalli D, Brown D, Majjaj S, Salgado R, Pusztai L, Harbeck N, El-Abed S, Sotiriou C. Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III clinical trial. Clin Cancer Res 2021
Jul 28, 2021Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III clinical trial
Jul 28, 2021Clin Cancer Res 2021
Venet David, Gomez Henry, Semiglazov Vladimir, de Azambuja Evandro, Huober Jens, Nuciforo Paolo, Di Cosimo Serena, Piccart-Gebhart Martine, Loi Sherene, Rothé Françoise, Saura Cristina, Wang Yingbo, Rediti Mattia, Maetens Marion, Fumagalli Debora, Brown David N, Majjaj Samira, Salgado Roberto, Pusztai Lajos, Harbeck Nadia, El-Abed Sarra, Sotiriou Christos
Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer
Chic N, Prat A, Huober J, Saura C, Di Cosimo S, Láng I, de Azambuja E, Wang Y, Hilbers F, Fumagalli D, Salgado R, Nuciforo P, Luen S, Loi S. Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer. J Natl Cancer Inst 2021
Mar 31, 2021Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer
Mar 31, 2021J Natl Cancer Inst 2021
Chic Nuria, Prat Aleix, Huober Jens, Saura Cristina, Di Cosimo Serena, Láng István, de Azambuja Evandro, Wang Yingbo, Hilbers Florentine, Fumagalli Debora, Salgado Roberto, Nuciforo Paolo, Luen Stephen J, Loi Sherene
Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial
Di Cosimo S, Daidone M, Piccart M, Izquierdo M, Fumagalli D, Huober J, Saura C, De Santis M, Franzoi M, Cinieri S, Agbor-Tarh D, Porcu L, de Azambuja E. Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial. Breast Cancer Res 2020; 22:115.
Oct 27, 2020Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial
Oct 27, 2020Breast Cancer Res 2020; 22:115
Di Cosimo Serena, Daidone Maria Grazia, Piccart Martine, Izquierdo Miguel, Fumagalli Debora, Huober Jens, Saura Cristina, De Santis Maria Carmen, Franzoi Maria Alice, Cinieri Saverio, Agbor-Tarh Dominique, Porcu Luca, de Azambuja Evandro
Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer
Huober J, Hackman J, Dasappa L, Ciruelos E, Toral Pena J, Adamchuk H, Hickish T, de la Pena L, Jackisch C, Gelber R, Piccart-Gebhart M, Jouannaud C, Wildiers H, Lecocq C, Holmes E, Baselga J, de Azambuja E, Untch M, Fumagalli D, Sarp S, Láng I, Smith I, Boyle F, Xu B, Di Cosimo S. Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. Eur J Cancer 2019; 118:169-177.
Aug 1, 2019Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer
Aug 1, 2019Eur J Cancer 2019; 118:169-177
Huober Jens, Hackman John, Dasappa Lokanatha, Ciruelos Eva, Toral Pena Juan Carlos, Adamchuk Hryhoriy, Hickish Tamas, de la Pena Lorena, Jackisch Christian, Gelber Richard D, Piccart-Gebhart Martine, Jouannaud Christelle, Wildiers Hans, Lecocq Christophe, Holmes Eileen, Baselga José, de Azambuja Evandro, Untch Michael, Fumagalli Debora, Sarp Severine, Láng István, Smith Ian, Boyle Frances, Xu Binghe, Di Cosimo Serena
The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study
Di Cosimo S, Gori S, Cinieri S, Torri V, Baselga J, Piccart M, de Braud F, Apolone G, Verderio P, Huober J, Daidone M, Peña L, Triulzi T, Pizzamiglio S, De Cecco L, de Azambuja E, Fumagalli D, Putzai L, Harbeck N, Izquierdo M, Tagliabue E. The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. Eur J Cancer 2019; 118:1-9.
Jul 5, 2019The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study
Jul 5, 2019Eur J Cancer 2019; 118:1-9
Di Cosimo Serena, Gori Stefania, Cinieri Saverio, Torri Valter, Baselga José, Piccart Martine, de Braud Filippo G, Apolone Giovanni, Verderio Paolo, Huober Jens, Daidone Maria Grazia, Peña Lorena de la, Triulzi Tiziana, Pizzamiglio Sara, De Cecco Loris, de Azambuja Evandro, Fumagalli Debora, Putzai Lajos, Harbeck Nadia, Izquierdo Miguel, Tagliabue Elda
Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Rothé F, Wardley A, Ueno T, Janni W, Huober J, Baselga J, Piccart M, Loi S, Sotiriou C, Dawson S, Chia S, Rosa D, Di Cosimo S, Silva M, Venet D, Campbell C, Bradburry I, Rouas G, de Azambuja E, Maetens M, Fumagalli D, Rodrik-Outmezguine V, Ignatiadis M. Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial. Clin Cancer Res 2019; 25:3581-3588.
Mar 12, 2019Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Mar 12, 2019Clin Cancer Res 2019; 25:3581-3588
Rothé Françoise, Wardley Andrew, Ueno Takayuki, Janni Wolfgang, Huober Jens, Baselga José, Piccart Martine, Loi Sherene, Sotiriou Christos, Dawson Sarah-Jane, Chia Stephen, Rosa Daniela, Di Cosimo Serena, Silva Maria Joao, Venet David, Campbell Christine, Bradburry Ian, Rouas Ghizlane, de Azambuja Evandro, Maetens Marion, Fumagalli Debora, Rodrik-Outmezguine Vanessa, Ignatiadis Michail
Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Powles R, Pusztai L, Elemento O, Piccart-Gebhart M, Baselga J, Huober J, Di Cosimo S, Sarp S, de Azambuja E, Harbeck N, Nuciforo P, Fumagalli D, Loi S, Sotiriou C, Redmond D, Hatzis C. Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 2018; 4:e181564.
Nov 8, 2018Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Nov 8, 2018JAMA Oncol 2018; 4:e181564
Powles Ryan L, Pusztai Lajos, Elemento Olivier, Piccart-Gebhart Martine, Baselga José, Huober Jens, Di Cosimo Serena, Sarp Severine, de Azambuja Evandro, Harbeck Nadia, Nuciforo Paolo, Fumagalli Debora, Loi Sherene, Sotiriou Christos, Redmond David, Hatzis Christos
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)
Ponde N, Maetens M, Harbeck N, Pusztai L, Berghorn M, Im Y, Borrego M, Chen D, Rodeheffer R, Piccart M, Suter T, Bozovic-Spasojevic I, Fumagalli D, Bradbury I, Lambertini M, Ewer M, Campbell C, Ameels H, Zardavas D, Di Cosimo S, Baselga J, Huober J, Izquierdo M, de Azambuja E. Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). Breast Cancer Res Treat 2017; 168:631-638.
Dec 27, 2017Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)
Dec 27, 2017Breast Cancer Res Treat 2017; 168:631-638
Ponde Noam, Maetens Marion, Harbeck Nadia, Pusztai Lajos, Berghorn Michael, Im Young-Hyuck, Borrego Manuel Ruiz, Chen Dar-Ren, Rodeheffer Richard, Piccart Martine, Suter Thomas, Bozovic-Spasojevic Ivana, Fumagalli Debora, Bradbury Ian, Lambertini Matteo, Ewer Michael, Campbell Christine, Ameels Helene, Zardavas Dimitrios, Di Cosimo Serena, Baselga José, Huober Jens, Izquierdo Miguel, de Azambuja Evandro
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Fumagalli D, Di Cosimo S, de Azambuja E, de la Pena L, Nuciforo P, Brase J, Huober J, Baselga J, Piccart M, Loi S, Coccia-Portugal M, Chang T, Gomez H, Venet D, Ignatiadis M, Azim H, Maetens M, Rothé F, Salgado R, Bradbury I, Pusztai L, Harbeck N, Sotiriou C. RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 2017; 3:227-234.
Feb 1, 2017RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Feb 1, 2017JAMA Oncol 2017; 3:227-234
Fumagalli Debora, Di Cosimo Serena, de Azambuja Evandro, de la Pena Lorena, Nuciforo Paolo, Brase Jan C, Huober Jens, Baselga José, Piccart Martine, Loi Sherene, Coccia-Portugal Maria Antonia, Chang Tsai-Wang, Gomez Henry, Venet David, Ignatiadis Michail, Azim Hatem A, Maetens Marion, Rothé Françoise, Salgado Roberto, Bradbury Ian, Pusztai Lajos, Harbeck Nadia, Sotiriou Christos